Sign in
Taking peopleNo phase

Radiation before surgery for cancer that has spread to the brain

Tests giving targeted radiation before surgery to adults with brain metastases.

Key facts

Who runs it
University Hospital Ostrava
Where
Czechia4 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis
Status
Recruiting
People taking part
260 people, planned
Started
1 May 2025
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Neoadjuvant Stereotactic Radiotherapy (NaSRT)
  • Postoperative Stereotactic Radiotherapy (SRT)
Record updated
4 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cancer that has spread to the brain. They get stereotactic radiotherapy (precisely aimed radiation) in several sessions before surgery to remove the brain tumour.

Age
18 years and older
Sex
All sexes
Disease stage
Brain metastases seen on MRI from a cancer confirmed by tissue testing. The main brain tumour must be planned for surgical removal and be between 1 cm (0.4 in) and 7 cm (2.8 in) at its longest. Any other spread must be treatable with high-dose stereotactic radiotherapy. Karnofsky Performance Status (a score of daily functioning) of 60 or more.
Earlier treatment
Cannot have had whole-brain radiotherapy (WBRT). Cannot have had stereotactic radiotherapy to the main brain tumour before.

Main reasons for not taking part

  • Confirmed blood cancer
  • Small-cell (lung) carcinoma
  • Very sudden, severe condition that needs brain surgery right away
  • Pregnancy
  • Surgery to remove the main brain tumour not possible within 7 days after the radiotherapy

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Karnofsky Performance Status ≥ 60
  • Histologically verified primary cancer disease
  • MRI findings indicating BM
  • Target BM indicated for surgical resection and any other metastases suitable for radical SRT
  • Target BM between 1 cm and 7 cm at the longest diameter on T1 post-contrast MR imaging

Who cannot take part

  • Inability to perform surgical resection of the target BM within 7 days after NaSRT
  • Peracute condition requiring immediate neurosurgical intervention
  • History of whole-brain radiotherapy (WBRT)
  • History of stereotactic radiotherapy to a target brain metastasis
  • Confirmed hematological malignity
  • Small-cell (lung) carcinoma
  • Pregnancy

This trial is currently available in Czechia.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.

The 2 groups in the trial

  • Neoadjuvant NaSRT - prospectiveTreatment being tested

    Patients undergoing neoadjuvant NaSRT will be enrolled prospectively in this study arm.

    Treatment: Neoadjuvant Stereotactic Radiotherapy (NaSRT)

  • Postoperative SRT - retrospectiveExisting treatment, for comparison

    Patients who underwent postoperative SRT in the past will be analyzed retrospectively in this study arm.

    Treatment: Postoperative Stereotactic Radiotherapy (SRT)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis - Prospective Trial NeoSTROBE
Plain-language title
Radiation before surgery for cancer that has spread to the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
4 May 2025